Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 7/20 | 0.48 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.48 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | BDNF | P23560 | 2/20 | 0.42 |
| ▸ | PTN | P21246 | 1/20 | 0.42 |
| ▸ | MDK | P21741 | 1/20 | 0.42 |
| ▸ | CD69 | Q07108 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.39 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.39 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.38 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5790851 | 0.86 | MDK (0.53) | LGALS3LGALS8LGALS4MAPK1BDNF | |
| SCHEMBL18079769 | 0.86 | MDK (0.53) | LGALS3LGALS8LGALS4MAPK1BDNF | |
| SCHEMBL29531877 | 0.86 | MDK (0.53) | LGALS3LGALS8LGALS4MAPK1BDNF | |
| SCHEMBL29535260 | 0.86 | MDK (0.53) | LGALS3LGALS8LGALS4MAPK1BDNF | |
| SCHEMBL30089312 | 0.84 | LGALS3 (0.54) | LGALS3LGALS8LGALS4MAPK1BDNF | |
| SCHEMBL29489963 | 0.83 | SELL (0.48) | LGALS3LGALS8LGALS4MAPK1BDNF | |
| SCHEMBL13321878 | 0.83 | MDK (0.61) | LGALS3LGALS8LGALS4MAPK1BDNF | |
| SCHEMBL29535351 | 0.82 | MAPK1 (0.53) | LGALS3LGALS8LGALS4MAPK1CD69 | |
| SCHEMBL29535303 | 0.82 | MAPK1 (0.53) | LGALS3LGALS8LGALS4MAPK1CD69 | |
| SCHEMBL10488345 | 0.81 | MAPK1 (0.65) | LGALS3LGALS8LGALS4MAPK1CD69 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220023325-A1 | SPECIFIC TLR4 ANTAGONIST IN THE TREATMENT OF MULTIPLE MYELOMA | UNIVERSITE PAUL SABATIER TOULOUSE III (FR) | 2022-01-27 | — | — | US | disclosed |
| US-20210128594-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATORY DISORDERS | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2021-05-06 | — | — | US | disclosed |
| US-10668092-B2 | Compositions and methods for treatment of inflammatory disorders | THE JOHN HOPKINS UNIVERSITY (US) | 2020-06-02 | — | — | US | disclosed |
| EP-3558323-A1 | SPECIFIC TLR4 ANTAGONIST IN THE TREATMENT OF MULTIPLE MYELOMA | Etablissement Français du Sang (FR) | 2019-10-30 | — | — | EP | disclosed |
| US-20180280418-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATORY DISORDERS | THE JOHNS HOPKINS UNIVERSITY | 2018-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180280418-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATORY DISORDERS | TLR4, TLR3, TLR2 | LGALS3 181/4885LGALS8 357/4885LGALS4 201/4885 |
| US-20220023325-A1 | SPECIFIC TLR4 ANTAGONIST IN THE TREATMENT OF MULTIPLE MYELOMA | TLR4, TLR3, TLR2 | LGALS3 503/4885LGALS8 526/4885LGALS4 154/4885 |
| US-10668092-B2 | Compositions and methods for treatment of inflammatory disorders | TLR4, TLR3, TLR2 | LGALS3 181/4885LGALS8 357/4885LGALS4 201/4885 |
| US-20210128594-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATORY DISORDERS | TLR4, TLR3, TLR2 | LGALS3 181/4885LGALS8 357/4885LGALS4 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.